HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding (NCT04867109) | Clinical Trial Compass
UnknownNot Applicable
HE4 in the Diagnostic Approach of Endometrial Cancer in Patients With Postmenopausal Bleeding
France100 participantsStarted 2021-06-25
Plain-language summary
This study aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in case of postmenopausal bleedings.
Who can participate
Age range18 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patient with postmenopausal bleeding
* Patient requiring hysteroscopy or hysterectomy
* No objection from the patient to participate in the study
Exclusion Criteria:
* Non-menopausal patient
* Patient under guardianship, curatorship or deprived of her freedom
* Patient with proven metastases on imaging
* Patient with a macroscopically suspicious cervix
* Patient presenting an ovarian cyst or an associated adnexal pathology
* Patient contraindicated for surgical treatment (therefore not eligible for pathological analysis)
* Patient who has already been treated with hormone therapy for breast cancer
* Patient who has already had surgery for this pathology, with a contributing anatomopathological result (we will therefore include patients who would not benefit from an operative hysteroscopy after performing a cornier® pipelle that does not allow a positive result)
What they're measuring
1
To evaluate the sensitivity of the HE4 marker in patients with postmenopausal bleeding in the diagnosis of endometrial cancer
Timeframe: Until the pathological results (About 10-15 days)